Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FibroGen, a biotechnology-based drug discovery company, has appointed Frank Valone as its new chief medical officer.
Subscribe to our email newsletter
Dr Valone was most recently senior vice president of medical affairs at Bayhill Therapeutics where he was responsible for clinical, regulatory, quality and nonclinical toxicology/safety aspects related to the development of Bayhill’s investigational therapies.
Prior to Bayhill, Dr Valone was executive vice president of clinical development and regulatory affairs of Titan Pharmaceuticals. Dr Valone has received a BA from Hamilton College and an MD from Harvard Medical School.
Thomas Neff, CEO of FibroGen, said: “With several ongoing clinical programs for our investigational small molecule and antibody therapies, Frank’s proven experience and success will be an important asset to FibroGen. We look forward to his contributions in helping us to advance our compounds through clinical development and on to approval and commercialization.”